This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Feuerstein's Biotech-Stock Mailbag

Welcome back to the Mailbag, which unfortunately was closed most of the week because I was in New York at the UBS Global Life Sciences Conference.

I'll return to your emails next week, but in the meantime, here are some reports and updates from the conference. This week:

  • Sangamo BioSciences (SGMO - Get Report)
  • Medarex (MEDX)
  • Dendreon (DNDN)
  • Telik (TELK)
  • Encysive Pharmaceuticals (ENCY)


Two institutional investor friends of mine brought up Sangamo this week in separate conversations. On the same day, my BlackBerry buzzed with an email from a retail investor and InvestorVillage.com message board poster informing me that he had "upgraded" Sangamo to "possibly the next Celgene (CELG - Get Report), but definitely the next Alnylam (ALNY)."

I haven't thought much about Sangamo since writing about the company in early August, so I looked at the chart and was surprised to see the stock's move from $10 to $14.

Memo to James Altucher: Sangamo is a rocket stock !

All kidding aside, Sangamo does have an interesting story to tell. As I described back in August, the company is engineering protein "switches" called zinc fingers that can turn genes on or off. It's similar to the work being done with RNA interference, or RNAi, with one big difference: RNAi can only turn genes off while zinc finger proteins have the ability to turn genes on and off.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,387.21 -291.49 -1.65%
S&P 500 2,029.55 -27.54 -1.34%
NASDAQ 4,681.4970 -90.2660 -1.89%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs